Viking Global Investors
SRPT icon

Viking Global Investors’s Sarepta Therapeutics SRPT Stock Holding History

Viking Global Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-668,175
Closed -$25.4M – 76
2013
Q2 		$25.4M Buy
+668,175
New +$23.9M 0.14% 54

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Viking Global Investors's SRPT Position: Q3 2013 in Review

Viking Global Investors sold out of Sarepta Therapeutics (SRPT) in Q3 2013, closing a stake of 668,175 shares — an estimated $25.4M sold.

Viking Global Investors first reported a position in SRPT in Q2 2013 and held it in 1 quarter. The position peaked at $25.4M in Q2 2013. 134 funds tracked by Wall St. Rank hold SRPT as of Q3 2013.

  • Viking Global Investors reported no remaining Sarepta Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Viking Global Investors sold 668,175 Sarepta Therapeutics shares in Q3 2013, an estimated $25.4M.
  • Viking Global Investors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 1 quarter.
  • Viking Global Investors's Sarepta Therapeutics position peaked at $25.4M in Q2 2013.
  • 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2013.

Based on Viking Global Investors's 13F filing for Q3 2013, filed 14 Nov 2013.